Independent Swiss drugmaker Nycomed has posted financial results for the third quarter of 2010, showing that turnover had reached 814.6 million euros ($1.14 billion), an increase of 8.7% (plus 1.5% in local currencies), excluding a one-time payment in the like 2009 period.
Adjusted EBITDA increased 1.2% (-9.8% in local currencies) excluding a one-time payment in Q3/2009. In euro, adjusted EBITDA was down by 23.9% to €217.1 million euros.
Nycomed says its strategy of focusing on emerging markets and specialty products is paying off. The third quarter results shows that the sales of key products and in emerging markets are continuing to help offset the impact from the loss of exclusivity of pantoprazole.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze